The resulting MHC transcriptional signature (MHC.sig) serves as a pan‐cancer predictor of immunotherapy response and a tool for identifying synergistic therapeutic targets, emphasizing the utility of multi‐omics approaches in MHC‐related research.189. This evidence concerns the gene HLA-C and cancer.